Getting your Trinity Audio player ready... The drugmaker Amgen has sued Colorado’s Prescription Drug Affordability Board for a second time, alleging that the board’s decision last month to set a price ...

Real-world data suggest anti-TNF biosimilars for juvenile idiopathic arthritis offer comparable efficacy and safety to their brand name counterparts. As high-cost originator biologics continue to ...

Patients with rheumatoid arthritis (RA) who switched from Enbrel (reference etanercept) to a biosimilar maintained remission, even after their dose was reduced, with no signs of worsening based on ...

Originally approved by the FDA in 1998, Amgen’s Enbrel is still sailing along without facing biosimilar competition in the United States. And unless a court rules otherwise, the Southern California ...

Please provide your email address to receive an email when new articles are posted on . In 2026, Stelara will be discounted 66% from its list price for Medicare users, while Enbrel will be discounted ...

“A 50-mg dose of Enbrel now costs patients $7,401.83 per month: 643% more than it cost when launched in 1998,” according to the allegations in the antitrust class action filed against Enbrel ...

Automobile engines have undergone tons of changes over the years, primarily to make them more efficient. For the most part though, engine changes result from a string of iterative improvements on ...

Lupin is introducing Rymti, its first biosimilar in Canada, through its partner Sandoz Canada (Sandoz). Rymti is indicated for the treatment of moderate to severe active rheumatoid arthritis, juvenile ...